A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis - Sorbonne Université Access content directly
Journal Articles Arthritis & rheumatology Year : 2019

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Roy Fleischmann
Henning Bliddal
  • Function : Author
Francisco Blanco
Thomas Schnitzer
  • Function : Author
Charles Peterfy
  • Function : Author
Su Chen
  • Function : Author
Li Wang
  • Function : Author
Sheng Feng
  • Function : Author
Philip Conaghan
  • Function : Author
Francis Berenbaum
Jean‐pierre Pelletier
  • Function : Author
Johanne Martel-Pelletier
  • Function : Author
Ole Vaeterlein
  • Function : Author
Gurjit Kaeley
  • Function : Author
Wei Liu
  • Function : Author
Matthew Kosloski
  • Function : Author
Gwen Levy
  • Function : Author
Lanju Zhang
  • Function : Author
Jeroen Medema
  • Function : Author
Marc Levesque
  • Function : Author

Dates and versions

hal-03994418 , version 1 (17-02-2023)

Identifiers

Cite

Roy Fleischmann, Henning Bliddal, Francisco Blanco, Thomas Schnitzer, Charles Peterfy, et al.. A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & rheumatology, 2019, 71 (7), pp.1056-1069. ⟨10.1002/art.40840⟩. ⟨hal-03994418⟩
8 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More